The ARDS, Pneumonia, and Sepsis Consortium: Rationale, Design, and Feasibility of a National Platform for Phenotyping Critical Illness Syndromes
Authors' conclusion
The APS Consortium Phenotyping Study is producing a cohort of critically ill adults with ARDS, pneumonia, and sepsis with high severity of disease and a rich set of data and biospecimens.
Study context
- Population
- Critically ill adults with ARDS, pneumonia, or sepsis
- Participants
- 1,000 first participants
- Outcome
- Feasibility: recruitment pace, participant characteristics, biospecimen collection, and proportion with confirmed ARDS, pneumonia, and sepsis by expert adjudication
Methodological detailsmulticentre, longitudinal, feasibility assessment of first 1,000 participants
- Multicentre
- Longitudinal
- Feasibility assessment of first 1,000 participants
Main finding
As reported in the abstract
Feasibility
- Recruitment of first 1,000 participants ahead of schedule (months)
- < 13
- Median age (years)
- 64
- Received vasopressors
- 75%
- Received invasive mechanical ventilation
- 50%
- In-hospital death within 4 weeks of enrolment
- 25%
- Blood samples
- 99%
- Upper respiratory swabs
- 98%
- Lower respiratory samples
- 37%
- Urine samples
- 80%
- Gastrointestinal samples
- 65%
- Adjudicated ARDS
- 40%
- Adjudicated pneumonia
- 52%
- Adjudicated sepsis
- 89%
Observational data: associations, not effects.
Original publication
The ARDS, Pneumonia, and Sepsis Consortium: Rationale, Design, and Feasibility of a National Platform for Phenotyping Critical Illness Syndromes. Chest. Published 13 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →